Literature DB >> 9467593

Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism.

R E Imseis1, L Vanmiddlesworth, J D Massie, A J Bush, N R Vanmiddlesworth.   

Abstract

Ninety-three hyperthyroid patients were treated with 1 dose of iodine-131 (131I) during the past 10 years. Thirty-three were pretreated with propylthiouracil (PTU), 22 with methimazole (MMI), and 38 received no antithyroid drugs (ATD). ATD were discontinued 5-55 days before 131I therapy in three fourths of the cases and more than 4 months before therapy in one fourth of the cases. The frequency of cures in the 3 groups, 6-8 months after radioiodine therapy, was retrospectively studied. The cure rate among those who discontinued PTU for 5-55 days before 131I was significantly reduced (24%), compared with those who discontinued MMI for the same duration (61%) or those who received no ATD (66%). When PTU was discontinued for more than 4 months, the cure rate was similar to those who received no ATD. It is concluded that if ATD are used as initial therapy for hyperthyroidism, then PTU (but not MMI) may reduce the therapeutic efficacy of subsequent 131I. The reduction in cure rate was observed even when PTU was discontinued for as long as 55 days before 131I therapy. To our knowledge, this is the first report to compare, in one study, the effects of pretreatment with PTU and MMI on 131I therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467593     DOI: 10.1210/jcem.83.2.4538

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

Review 1.  Antithyroid drug treatment prior to radioiodine therapy for Graves' disease: yes or no?

Authors:  F Bogazzi; E Martino; L Bartalena
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

2.  Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves' disease.

Authors:  Simone Dunkelmann; Hubertus Kuenstner; Elham Nabavi; Bettina Rohde; Peter Groth; Carl Schuemichen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-09-22       Impact factor: 9.236

3.  Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials.

Authors:  Martin A Walter; Matthias Briel; Mirjam Christ-Crain; Steen J Bonnema; John Connell; David S Cooper; Heiner C Bucher; Jan Müller-Brand; Beat Müller
Journal:  BMJ       Date:  2007-02-19

4.  Greater Efficacy of Total Thyroidectomy versus Radioiodine Therapy on Hyperthyroidism and Thyroid-Stimulating Immunoglobulin Levels in Patients with Graves' Disease Previously Treated with Antithyroid Drugs.

Authors:  Shakeel Kautbally; Orsalia Alexopoulou; Chantal Daumerie; François Jamar; Michel Mourad; Dominique Maiter
Journal:  Eur Thyroid J       Date:  2012-06-20

5.  Long-term outcome of Graves' disease patients treated in a region with iodine deficiency: relapse rate increases in years with thionamides.

Authors:  Neslihan Basçil Tütüncü; Tanju Tütüncü; Ali Ozgen; Tomris Erbas
Journal:  J Natl Med Assoc       Date:  2006-06       Impact factor: 1.798

6.  Effectiveness of radioiodine (131-I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism.

Authors:  B Tarantini; C Ciuoli; G Di Cairano; E Guarino; P Mazzucato; A Montanaro; L Burroni; A G Vattimo; F Pacini
Journal:  J Endocrinol Invest       Date:  2006 Jul-Aug       Impact factor: 4.256

7.  Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison.

Authors:  Martin A Walter; Mirjam Christ-Crain; Christian Schindler; Jan Müller-Brand; Beat Müller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-11       Impact factor: 9.236

8.  Current and emerging treatment options for Graves' hyperthyroidism.

Authors:  Prakash Abraham; Shamasunder Acharya
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

9.  Failure of radioactive iodine in the treatment of hyperthyroidism.

Authors:  David F Schneider; Philip E Sonderman; Michaela F Jones; Kristin A Ojomo; Herbert Chen; Juan C Jaume; Diane F Elson; Scott B Perlman; Rebecca S Sippel
Journal:  Ann Surg Oncol       Date:  2014-07-08       Impact factor: 5.344

10.  Radioiodine I-131 for the therapy of graves' disease.

Authors:  Malik Mumtaz; Lim Shueh Lin; Khaw Chong Hui; Amir Sharifuddin Mohd Khir
Journal:  Malays J Med Sci       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.